{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:09:00Z","timestamp":1789070940331,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"DOI":"10.1038\/s44161-026-00866-8","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:02:17Z","timestamp":1788253337000},"page":"891-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multiancestry polygenic risk score improves stratification in patients with hypertrophic cardiomyopathy"],"prefix":"10.1038","volume":"5","author":[{"given":"Harshvir S.","family":"Bal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4167-0540","authenticated-orcid":false,"given":"Akhil","family":"Pampana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mokshad","family":"Gaonkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahaj","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishin","family":"Yerabolu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal","family":"Vekariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirav","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajat","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9026-9999","authenticated-orcid":false,"given":"Peng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garima","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2420-3550","authenticated-orcid":false,"given":"Pankaj","family":"Arora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"866_CR1","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41588-020-00764-0","volume":"53","author":"AR Harper","year":"2021","unstructured":"Harper, A. R. et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat. Genet. 53, 135\u2013142 (2021).","journal-title":"Nat. Genet."},{"key":"866_CR2","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 65, 1249\u20131254 (2015).","journal-title":"J. Am. Coll. Cardiol."},{"key":"866_CR3","first-page":"e558","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen, S. R. et al. 2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142, e558\u2013e631 (2020).","journal-title":"Circulation"},{"key":"866_CR4","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"Authors\/Task Force members","year":"2014","unstructured":"Authors\/Task Force members 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur. Heart J. 35, 2733\u20132779 (2014).","journal-title":"Eur. Heart J."},{"key":"866_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41588-025-02094-5","volume":"57","author":"SL Zheng","year":"2025","unstructured":"Zheng, S. L. et al. Evaluation of polygenic scores for hypertrophic cardiomyopathy in the general population and across clinical settings. Nat. Genet. 57, 563\u2013571 (2025).","journal-title":"Nat. Genet."},{"key":"866_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1161\/CIRCRESAHA.117.311059","volume":"121","author":"AJ Marian","year":"2017","unstructured":"Marian, A. J. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749\u2013770 (2017).","journal-title":"Circ. Res."},{"key":"866_CR7","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/j.jacc.2021.07.017","volume":"78","author":"A de Marvao","year":"2021","unstructured":"de Marvao, A. et al. Phenotypic expression and outcomes in individuals with rare genetic variants of hypertrophic cardiomyopathy. J. Am. Coll. Cardiol. 78, 1097\u20131110 (2021).","journal-title":"J. Am. Coll. Cardiol."},{"key":"866_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41569-020-0428-2","volume":"18","author":"WJ McKenna","year":"2021","unstructured":"McKenna, W. J. & Judge, D. P. Epidemiology of the inherited cardiomyopathies. Nat. Rev. Cardiol. 18, 22\u201336 (2021).","journal-title":"Nat. Rev. Cardiol."},{"key":"866_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1038\/s41436-018-0375-z","volume":"21","author":"KL Thomson","year":"2019","unstructured":"Thomson, K. L. et al. Analysis of 51 proposed hypertrophic cardiomyopathy genes from genome sequencing data in sarcomere negative cases has negligible diagnostic yield. Genet. Med. 21, 1576\u20131584 (2019).","journal-title":"Genet. Med."},{"key":"866_CR10","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/gim.2014.205","volume":"17","author":"AA Alfares","year":"2015","unstructured":"Alfares, A. A. et al. Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity. Genet. Med. 17, 880\u2013888 (2015).","journal-title":"Genet. Med."},{"key":"866_CR11","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/gim.2016.90","volume":"19","author":"R Walsh","year":"2017","unstructured":"Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. Genet. Med. 19, 192\u2013203 (2017).","journal-title":"Genet. Med."},{"key":"866_CR12","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamacardio.2022.1061","volume":"7","author":"KJ Biddinger","year":"2022","unstructured":"Biddinger, K. J. et al. Rare and common genetic variation underlying the risk of hypertrophic cardiomyopathy in a national biobank. JAMA Cardiol. 7, 715\u2013722 (2022).","journal-title":"JAMA Cardiol."},{"key":"866_CR13","doi-asserted-by":"crossref","unstructured":"Mazzarotto, F. et al. Contemporary insights into the genetics of hypertrophic cardiomyopathy: toward a new era in clinical testing? J. Am. Heart Assoc. 9, e015473 (2020).","DOI":"10.1161\/JAHA.119.015473"},{"key":"866_CR14","unstructured":"Tadros, R. et al. Large scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy. Nat. Genet. 57, 530\u2013538 (2025)."},{"key":"866_CR15","unstructured":"Verma, A. et al. Diversity and scale: genetic architecture of 2068 traits in the VA Million Veteran Program. Science 385, eadj1182 (2024)."},{"key":"866_CR16","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41588-021-00931-x","volume":"53","author":"S Sakaue","year":"2021","unstructured":"Sakaue, S. et al. A cross-population atlas of genetic associations for 220 human phenotypes. Nat. Genet. 53, 1415\u20131424 (2021).","journal-title":"Nat. Genet."},{"key":"866_CR17","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s41588-020-00762-2","volume":"53","author":"R Tadros","year":"2021","unstructured":"Tadros, R. et al. Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nat. Genet. 53, 128\u2013134 (2021).","journal-title":"Nat. Genet."},{"key":"866_CR18","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1038\/s41591-023-02429-x","volume":"29","author":"AP Patel","year":"2023","unstructured":"Patel, A. P. et al. A multi-ancestry polygenic risk score improves risk prediction for coronary artery disease. Nat. Med. 29, 1793\u20131803 (2023).","journal-title":"Nat. Med."},{"key":"866_CR19","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/s41588-022-01036-9","volume":"54","author":"O Weissbrod","year":"2022","unstructured":"Weissbrod, O. et al. Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. Nat. Genet. 54, 450\u2013458 (2022).","journal-title":"Nat. Genet."},{"key":"866_CR20","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.1038\/s41467-023-38930-7","volume":"14","author":"B Lehmann","year":"2023","unstructured":"Lehmann, B., Mackintosh, M., McVean, G. & Holmes, C. Optimal strategies for learning multi-ancestry polygenic scores vary across traits. Nat. Commun. 14, 4023 (2023).","journal-title":"Nat. Commun."},{"key":"866_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41588-022-01054-7","volume":"54","author":"Y Ruan","year":"2022","unstructured":"Ruan, Y. et al. Improving polygenic prediction in ancestrally diverse populations. Nat. Genet. 54, 573\u2013580 (2022).","journal-title":"Nat. Genet."},{"key":"866_CR22","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1093\/eurheartj\/ehq271","volume":"31","author":"P Charron","year":"2010","unstructured":"Charron, P. et al. Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur. Heart J. 31, 2715\u20132726 (2010).","journal-title":"Eur. Heart J."},{"key":"866_CR23","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1161\/CIRCULATIONAHA.117.033200","volume":"138","author":"CY Ho","year":"2018","unstructured":"Ho, C. Y. et al. Genotype and lifetime burden of disease in hypertrophic cardiomyopathy: insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe). Circulation 138, 1387\u20131398 (2018).","journal-title":"Circulation"},{"key":"866_CR24","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1038\/s41467-019-09718-5","volume":"10","author":"T Ge","year":"2019","unstructured":"Ge, T., Chen, C. Y., Ni, Y., Feng, Y. A. & Smoller, J. W. Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. 10, 1776 (2019).","journal-title":"Nat. Commun."},{"key":"866_CR25","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1038\/s41596-020-0353-1","volume":"15","author":"SW Choi","year":"2020","unstructured":"Choi, S. W., Mak, T. S. & O\u2019Reilly, P. F. Tutorial: a guide to performing polygenic risk score analyses. Nat. Protoc. 15, 2759\u20132772 (2020).","journal-title":"Nat. Protoc."},{"key":"866_CR26","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron, B. J. et al. Diagnosis and evaluation of hypertrophic cardiomyopathy: JACC state-of-the-art review. J. Am. Coll. Cardiol. 79, 372\u2013389 (2022).","journal-title":"J. Am. Coll. Cardiol."},{"key":"866_CR27","doi-asserted-by":"publisher","first-page":"5146","DOI":"10.1093\/eurheartj\/ehad372","volume":"44","author":"M Allouba","year":"2023","unstructured":"Allouba, M. et al. Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy. Eur. Heart J. 44, 5146\u20135158 (2023).","journal-title":"Eur. Heart J."},{"key":"866_CR28","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1001\/jamacardio.2017.5333","volume":"3","author":"LG Landry","year":"2018","unstructured":"Landry, L. G. & Rehm, H. L. Association of racial\/ethnic categories with the ability of genetic tests to detect a cause of cardiomyopathy. JAMA Cardiol. 3, 341\u2013345 (2018).","journal-title":"JAMA Cardiol."},{"key":"866_CR29","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMsa1507092","volume":"375","author":"AK Manrai","year":"2016","unstructured":"Manrai, A. K. et al. Genetic misdiagnoses and the potential for health disparities. N. Engl. J. Med. 375, 655\u2013665 (2016).","journal-title":"N. Engl. J. Med."},{"key":"866_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1001\/jamacardio.2019.4638","volume":"5","author":"LA Eberly","year":"2020","unstructured":"Eberly, L. A. et al. Association of race with disease expression and clinical outcomes among patients with hypertrophic cardiomyopathy. JAMA Cardiol. 5, 83\u201391 (2020).","journal-title":"JAMA Cardiol."},{"key":"866_CR31","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1038\/s41467-020-17719-y","volume":"11","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Theoretical and empirical quantification of the accuracy of polygenic scores in ancestry divergent populations. Nat. Commun. 11, 3865 (2020).","journal-title":"Nat. Commun."},{"key":"866_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41586-023-06079-4","volume":"618","author":"Y Ding","year":"2023","unstructured":"Ding, Y. et al. Polygenic scoring accuracy varies across the genetic ancestry continuum. Nature 618, 774\u2013781 (2023).","journal-title":"Nature"},{"key":"866_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.ajhg.2017.03.004","volume":"100","author":"AR Martin","year":"2017","unstructured":"Martin, A. R. et al. Human demographic history impacts genetic risk prediction across diverse populations. Am. J. Hum. Genet. 100, 635\u2013649 (2017).","journal-title":"Am. J. Hum. Genet."},{"key":"866_CR34","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/S2213-8587(25)00405-X","volume":"14","author":"A Huerta-Chagoya","year":"2026","unstructured":"Huerta-Chagoya, A. et al. Multi-ancestry polygenic risk scores for the prediction of type 2 diabetes and complications in diverse ancestries. Lancet Diabetes Endocrinol. 14, 558\u2013569 (2026).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"866_CR35","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1038\/s41588-024-01870-z","volume":"56","author":"K Yuan","year":"2024","unstructured":"Yuan, K. et al. Fine-mapping across diverse ancestries drives the discovery of putative causal variants underlying human complex traits and diseases. Nat. Genet. 56, 1841\u20131850 (2024).","journal-title":"Nat. Genet."},{"key":"866_CR36","doi-asserted-by":"crossref","unstructured":"Forde, A., Hemani, G. & Ferguson, J. Review and further developments in statistical corrections for Winner\u2019s Curse in genetic association studies. PLoS Genet. 19, e1010546 (2023).","DOI":"10.1371\/journal.pgen.1010546"},{"key":"866_CR37","unstructured":"Shi, J. et al. Winner\u2019s Curse correction and variable thresholding improve performance of polygenic risk modeling based on genome-wide association study summary-level data. PLoS Genet. 12, e1006493 (2016)."},{"key":"866_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41576-023-00637-2","volume":"25","author":"L Kachuri","year":"2024","unstructured":"Kachuri, L. et al. Principles and methods for transferring polygenic risk scores across global populations. Nat. Rev. Genet. 25, 8\u201325 (2024).","journal-title":"Nat. Rev. Genet."},{"key":"866_CR39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/oxfordjournals.eurheartj.a060920","volume":"16","author":"AJ Marian","year":"1995","unstructured":"Marian, A. J. et al. Sudden cardiac death in hypertrophic cardiomyopathy. Variability in phenotypic expression of beta-myosin heavy chain mutations. Eur. Heart J. 16, 368\u2013376 (1995).","journal-title":"Eur. Heart J."},{"key":"866_CR40","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/S0735-1097(01)01389-4","volume":"38","author":"AJ Marian","year":"2001","unstructured":"Marian, A. J. On genetic and phenotypic variability of hypertrophic cardiomyopathy: nature versus nurture. J. Am. Coll. Cardiol. 38, 331\u2013334 (2001).","journal-title":"J. Am. Coll. Cardiol."},{"key":"866_CR41","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/j.mayocp.2024.05.026","volume":"99","author":"N Patel","year":"2024","unstructured":"Patel, N. et al. Sex-associated differences in clinical outcomes after septal reduction therapies in hypertrophic cardiomyopathy. Mayo Clin. Proc. 99, 1933\u20131944 (2024).","journal-title":"Mayo Clin. Proc."},{"key":"866_CR42","doi-asserted-by":"publisher","first-page":"e036387","DOI":"10.1161\/JAHA.124.036387","volume":"13","author":"N Patel","year":"2024","unstructured":"Patel, N. et al. Procedural volume and outcomes after septal reduction therapies in hypertrophic obstructive cardiomyopathy. J. Am. Heart Assoc. 13, e036387 (2024).","journal-title":"J. Am. Heart Assoc."},{"key":"866_CR43","doi-asserted-by":"publisher","first-page":"e005113","DOI":"10.1161\/CIRCGEN.124.005113","volume":"18","author":"NS Shetty","year":"2025","unstructured":"Shetty, N. S. et al. Association of pathogenic\/likely pathogenic genetic variants for cardiomyopathies with clinical outcomes: a multiancestry analysis in the All of Us Research Program. Circ. Genom. Precis. Med. 18, e005113 (2025).","journal-title":"Circ. Genom. Precis. Med."},{"key":"866_CR44","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.mayocp.2024.12.018","volume":"101","author":"N Patel","year":"2025","unstructured":"Patel, N. Cardiovascular health and outcomes in carriers with genetic variants of hypertrophic cardiomyopathy. Mayo Clin. Proc. 101, 73\u201384 (2025).","journal-title":"Mayo Clin. Proc."},{"key":"866_CR45","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1056\/NEJM199204233261703","volume":"326","author":"H Watkins","year":"1992","unstructured":"Watkins, H. et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N. Engl. J. Med. 326, 1108\u20131114 (1992).","journal-title":"N. Engl. J. Med."},{"key":"866_CR46","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1016\/j.jacc.2014.09.059","volume":"64","author":"R Coppini","year":"2014","unstructured":"Coppini, R. et al. Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. J. Am. Coll. Cardiol. 64, 2589\u20132600 (2014).","journal-title":"J. Am. Coll. Cardiol."},{"key":"866_CR47","doi-asserted-by":"crossref","unstructured":"Weissler-Snir, A., Dorian, P., Rakowski, H., Care, M. & Spears, D. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy\u2014are there predictors of appropriate therapy? Heart Rhythm 18, 63\u201370 (2021).","DOI":"10.1016\/j.hrthm.2020.08.009"},{"key":"866_CR48","doi-asserted-by":"crossref","unstructured":"Abramowitz, S. A. Polygenic background and penetrance of pathogenic variants in hypertrophic and dilated cardiomyopathies. JAMA Cardiol. 11, 147\u2013155 (2026).","DOI":"10.1101\/2025.06.20.25329138"},{"key":"866_CR49","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1161\/CIRCRESAHA.119.313569","volume":"124","author":"GG Repetti","year":"2019","unstructured":"Repetti, G. G., Toepfer, C. N., Seidman, J. G. & Seidman, C. E. Novel therapies for prevention and early treatment of cardiomyopathies. Circ. Res. 124, 1536\u20131550 (2019).","journal-title":"Circ. Res."},{"key":"866_CR50","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41591-022-02190-7","volume":"29","author":"D Reichart","year":"2023","unstructured":"Reichart, D. et al. Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice. Nat. Med. 29, 412\u2013421 (2023).","journal-title":"Nat. Med."},{"key":"866_CR51","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai, M. Y. et al. Mavacamten in patients with hypertrophic cardiomyopathy referred for septal reduction: week 56 results from the VALOR-HCM randomized clinical trial. JAMA Cardiol. 8, 968\u2013977 (2023).","journal-title":"JAMA Cardiol."},{"key":"866_CR52","doi-asserted-by":"crossref","unstructured":"Patel, N. Clinical outcomes with mavacamten use in patients with obstructive hypertrophic cardiomyopathy using real-world data. Mayo Clin. Proc. 101, 284\u2013294 (2025).","DOI":"10.1016\/j.mayocp.2025.01.003"},{"key":"866_CR53","doi-asserted-by":"crossref","unstructured":"Cirino, A. L. A comparison of whole genome sequencing to multigene panel testing in hypertrophic cardiomyopathy patients. Circ. Cardiovasc. Genet. 10, e001768 (2017).","DOI":"10.1161\/CIRCGENETICS.117.001768"},{"key":"866_CR54","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1056\/NEJMsr1809937","volume":"381","author":"All of Us Research Program Investigators.","year":"2019","unstructured":"All of Us Research Program Investigators. The \u201cAll of Us\u201d Research Program. N. Engl. J. Med. 381, 668\u2013676 (2019).","journal-title":"N. Engl. J. Med."},{"key":"866_CR55","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1038\/s41586-023-06957-x","volume":"627","author":"All of Us Research Program Genomics Investigators.","year":"2024","unstructured":"All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. Nature 627, 340\u2013346 (2024).","journal-title":"Nature"},{"key":"866_CR56","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41586-018-0579-z","volume":"562","author":"C Bycroft","year":"2018","unstructured":"Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data. Nature 562, 203\u2013209 (2018).","journal-title":"Nature"},{"key":"866_CR57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41586-025-09272-9","volume":"645","author":"Consortium, U. K. B. W.-G. S.","year":"2025","unstructured":"Consortium, U. K. B. W.-G. S. Whole-genome sequencing of 490,640 UK Biobank participants. Nature 645, 692\u2013701 (2025).","journal-title":"Nature"},{"key":"866_CR58","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards, S. et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 17, 405\u2013424 (2015).","journal-title":"Genet. Med."},{"key":"866_CR59","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/ng.3622","volume":"48","author":"W van Rheenen","year":"2016","unstructured":"van Rheenen, W. et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat. Genet. 48, 1043\u20131048 (2016).","journal-title":"Nat. Genet."},{"key":"866_CR60","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/ng.3719","volume":"49","author":"S Schafer","year":"2017","unstructured":"Schafer, S. et al. Titin-truncating variants affect heart function in disease cohorts and the general population. Nat. Genet. 49, 46\u201353 (2017).","journal-title":"Nat. Genet."},{"key":"866_CR61","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1161\/HYPERTENSIONAHA.111.181990","volume":"59","author":"E Salvi","year":"2012","unstructured":"Salvi, E. et al. Genomewide association study using a high-density single nucleotide polymorphism array and case\u2013control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase. Hypertension 59, 248\u2013255 (2012).","journal-title":"Hypertension"},{"key":"866_CR62","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41586-020-2434-2","volume":"583","author":"E Turro","year":"2020","unstructured":"Turro, E. et al. Whole-genome sequencing of patients with rare diseases in a national health system. Nature 583, 96\u2013102 (2020).","journal-title":"Nature"},{"key":"866_CR63","doi-asserted-by":"publisher","first-page":"e003946","DOI":"10.1161\/CIRCGEN.122.003946","volume":"15","author":"V Parcha","year":"2022","unstructured":"Parcha, V. et al. Association of a multiancestry genome-wide blood pressure polygenic risk score with adverse cardiovascular events. Circ. Genom. Precis. Med. 15, e003946 (2022).","journal-title":"Circ. Genom. Precis. Med."},{"key":"866_CR64","doi-asserted-by":"publisher","first-page":"e002460","DOI":"10.1161\/CIRCGEN.119.002460","volume":"12","author":"J Ingles","year":"2019","unstructured":"Ingles, J. et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ. Genom. Precis. Med. 12, e002460 (2019).","journal-title":"Circ. Genom. Precis. Med."},{"key":"866_CR65","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4161\/fly.19695","volume":"6","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin) 6, 80\u201392 (2012).","journal-title":"Fly (Austin)"},{"key":"866_CR66","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/j.mayocp.2025.01.021","volume":"100","author":"NS Shetty","year":"2025","unstructured":"Shetty, N. S. et al. Association of pathogenic\/likely pathogenic inherited cardiomyopathy variants with heart failure: a TOPMed multiancestry analysis. Mayo Clin. Proc. 100, 1948\u20131955 (2025).","journal-title":"Mayo Clin. Proc."},{"key":"866_CR67","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1038\/gim.2017.26","volume":"19","author":"N Whiffin","year":"2017","unstructured":"Whiffin, N. et al. Using high-resolution variant frequencies to empower clinical genome interpretation. Genet. Med. 19, 1151\u20131158 (2017).","journal-title":"Genet. Med."},{"key":"866_CR68","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1002\/cphg.93","volume":"103","author":"SM Harrison","year":"2019","unstructured":"Harrison, S. M., Biesecker, L. G. & Rehm, H. L. Overview of specifications to the ACMG\/AMP variant interpretation guidelines. Curr. Protoc. Hum. Genet. 103, e93 (2019).","journal-title":"Curr. Protoc. Hum. Genet."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00866-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00866-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00866-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:43:26Z","timestamp":1789069406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00866-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":68,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["866"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00866-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8951716\/v1","asserted-by":"object"}]},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"23 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.A. is supported by the National Heart, Lung, and Blood Institute of the National Institute of Health awards (R01HL160982, R01HL163852, R01HL163081, R01HL176882, K24HL180320, U01HG014610 and R01HL184037). P.A. reports grant support from Bristol-Myers Squibb, Cytokinetics Inc., Kardigan Inc. and Alexion Pharmaceuticals, Inc.; consulting income from Bristol-Myers Squibb; and serves as an advisory board member for BridgeBio and AstraZeneca, which are all unrelated to this work. The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}